Creatine 1g tablets
An amino acid derivative that occurs in vertebrate tissues and in urine.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Creatine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(15)
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
Migalastat for treating Fabry disease (HST4)
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Familial hypercholesterolaemia: identification and management (CG71)
Telbivudine for the treatment of chronic hepatitis B (TA154)
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)
Sparsentan for treating primary IgA nephropathy (TA1074)
Parkinson's disease in adults (NG71)
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)
Reslizumab for treating severe eosinophilic asthma (TA479)
Actim Pancreatitis for diagnosing acute pancreatitis (MIB218)
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)
Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) (HTG544)
Suspected neurological conditions: recognition and referral (NG127)
Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 48 · Randomised trials: 1 · 1985–2026
Showing the 50 most relevant studies, sorted by most relevant.
K. Avgerinos, N. Spyrou, K. Bougioukas, et al.
Experimental gerontology, 2018
R. Kreider, D. Kalman, J. Antonio, et al.
Journal of the International Society of Sports Nutrition, 2017
Guoyao Wu
Amino Acids, 2020
L. Kazak, P. Cohen
Nature Reviews Endocrinology, 2020
R. Kreider, J. Stout
Nutrients, 2021
P. Chilibeck, M. Kaviani, D. Candow, et al.
Open Access Journal of Sports Medicine, 2017
S. Moghadam-Kia, C. Oddis, R. Aggarwal
Cleveland Clinic journal of medicine, 2016
J. Antonio, D. Candow, Scott C. Forbes, et al.
Journal of the International Society of Sports Nutrition, 2021
de Camargo KMR, Bruna-Mejías A, Valenzuela-Fuenzalida JJ, et al.
2026
- Inflammation
- Creatine
- Dietary Supplements
IntroductionCreatine supplementation is widely recognized for its ergogenic effects on strength and body composition. Recent studies have explored its potential anti-inflammatory properties, particularly in exercise-induced stress and aging-related chronic inflammation. However, results across randomized trials remain inconsistent. This systematic review and meta-analysis aimed to assess the effects of creatine supplementation on inflammatory biomarkers in human populations.MethodsA systematic review and meta-analysis were conducted following PRISMA 2020 guidelines and registered in PROSPERO (CRD420251027784). Eight randomized controlled trials were included, evaluating creatine supplementation (various dosages and durations) versus placebo in healthy individuals, athletes, and clinical populations. The primary outcomes were inflammatory markers, including C-reactive protein (CRP), interleukin-6 (IL-6), IL-1β, TNF-α, and prostaglandin E2. Data extraction and risk of bias assessments were performed by two independent reviewers. The certainty of evidence was rated using the GRADE framework.ResultsPooled analysis showed no significant acute effects of creatine on CRP (SMD = 0.32; 95% CI: -0.29 to 0.94; p = 0.30; I² = 28%). Chronic effects of creatine on CRP (SMD = -0.11; 95% CI: -0.69 to 0.48; p = 0.73; I² = 0%) and IL-6 (SMD = -0.06; 95% CI: -0.64 to 0.53; p = 0.84; I² = 0%) were also no significant. The certainty of evidence was rated as moderate for all outcomes. Risk of bias varied, with missing outcome data being the most frequent limitation.ConclusionCreatine supplementation does not significantly reduce inflammatory biomarkers in humans based on current evidence. Although certain benefits were observed under intense endurance conditions, results remain inconsistent across populations. Future well-powered trials with standardized protocols are needed to clarify creatine's role in modulating inflammation.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420251027784.
Abstract licence: CC BY
Hoffman ID, Combs K
2026
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
3 hours
Mechanism
In the muscles, a fraction of the total creatine binds to phosphate - forming creatine phosphate.
Food interactions
None known
Human targets
5 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
3 hours
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:8186255
Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa (Probable). Acts as a key regulator of adaptive thermogenesis as part of the futile creatine cycle: localizes to the mitochondria of thermogenic fat cells and acts by mediating phosphorylation of creatine to initiate a futile cycle of creatine phosphorylation and dephosphorylation (By similarity). During the futile creatine cycle, creatine and N-phosphocreatine are in a futile cycle, which dissipates the high energy charge of N-phosphocreatine as heat without performing any mechanical or chemical work (By similarity)
PMID:24415674 PMID:26003046 PMID:26319512
Important in nervous system development PMID:24415674
Proteins that transport this drug across cell membranes
PMID:10454528 PMID:10525100 PMID:10966938 PMID:17509700 PMID:20722056 PMID:33124720
Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium.
Relative uptake activity ratio of carnitine to TEA is 11.3 .
PMID:10454528 PMID:10525100 PMID:10966938
In intestinal epithelia, transports the quorum-sensing pentapeptide CSF (competence and sporulation factor) from B.subtilis which induces cytoprotective heat shock proteins contributing to intestinal homeostasis .
PMID:18005709
May also contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier (Probable)
PMID:17465020 PMID:22644605 PMID:25861866 PMID:7945388 PMID:7953292 PMID:9882430
Plays an important role in supplying creatine to the brain via the blood-brain barrier (By similarity)
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Creatine
Additional database identifiers
ChemSpider
566
BindingDB
50357229
PDB
CRN
ZINC
ZINC000003861770
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1994
GenAtlas
CKM
GeneCards
CKM
GenBank Gene Database
M14780
GenBank Protein Database
180576
UniProt Accession
KCRM_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1995
GenAtlas
CKMT1A
GeneCards
CKMT1B
GenBank Gene Database
J04469
GenBank Protein Database
180590
UniProt Accession
KCRU_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1991
GenAtlas
CKB
GeneCards
CKB
GenBank Gene Database
M16451
GenBank Protein Database
180572
UniProt Accession
KCRB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1996
GenAtlas
CKMT2
GeneCards
CKMT2
GenBank Gene Database
J05401
GenBank Protein Database
338237
UniProt Accession
KCRS_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4136
GenAtlas
GAMT
GeneCards
GAMT
GenBank Gene Database
Z49878
GenBank Protein Database
1212946
UniProt Accession
GAMT_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10969
GenAtlas
SLC22A5
GeneCards
SLC22A5
GenBank Gene Database
AF057164
GenBank Protein Database
3273741
UniProt Accession
S22A5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11055
GenAtlas
SLC6A8
GeneCards
SLC6A8
GenBank Gene Database
L31409
GenBank Protein Database
493132
UniProt Accession
SC6A8_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72